These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9739765)

  • 1. [Subcutaneous manifestations of a centrocytic non-Hodgkin lymphoma at the injection site of a mistletoe preparation].
    Hagenah W; Dörges I; Gafumbegete E; Wagner T
    Dtsch Med Wochenschr; 1998 Aug; 123(34-35):1001-4. PubMed ID: 9739765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating unconventional therapies.
    Hajto T; Saller R
    CMAJ; 1998 Oct; 159(7):759; author reply 759, 761. PubMed ID: 9805018
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
    Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
    Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
    Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
    Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe?
    Gabius HJ; Gabius S; Joshi SS; Koch B; Schroeder M; Manzke WM; Westerhausen M
    Planta Med; 1994 Feb; 60(1):2-7. PubMed ID: 8134410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ingredients of mistletoe (Viscum album L.) as potential drugs].
    Franz H
    Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937
    [No Abstract]   [Full Text] [Related]  

  • 8. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks.
    Stoss M; van Wely M; Musielsky H; Gorter RW
    Arzneimittelforschung; 1999 Apr; 49(4):366-73. PubMed ID: 10337457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internalization and action of an immunotoxin containing mistletoe lectin A-chain.
    Wiedłocha A; Sandvig K; Walzel H; Radzikowsky C; Olsnes S
    Cancer Res; 1991 Feb; 51(3):916-20. PubMed ID: 1988131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
    Dohmen W; Breier M; Mengs U
    Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential binding of toxic lectins from Viscum album L., ML I and ML III, to human lymphocytes.
    Büssing A; Stein GM; Pfüller U; Schietzel M
    Anticancer Res; 1999; 19(6B):5095-9. PubMed ID: 10697516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallization of the ribosome inactivating protein ML1 from Viscum album (mistletoe) complexed with beta-D-galactose.
    Sweeney EC; Palmer RA; Pfüller U
    J Mol Biol; 1993 Dec; 234(4):1279-81. PubMed ID: 8263931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract.
    Stein GM; Berg PA
    Eur J Med Res; 1998 Jun; 3(6):307-14. PubMed ID: 9620894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
    Gabius S; Gabius HJ
    Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
    [No Abstract]   [Full Text] [Related]  

  • 15. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1.
    Beuth J; Ko HL; Tunggal L; Steuer MK; Geisel J; Jeljaszewicz J; Pulverer G
    In Vivo; 1993; 7(5):407-10. PubMed ID: 8110981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viscotoxin-free aqueous extracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes.
    Stein GM; Pfüller U; Schietzel M
    Anticancer Res; 1999; 19(4B):2925-8. PubMed ID: 10652574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.
    Goebell PJ; Otto T; Suhr J; Rübben H
    J Urol; 2002 Jul; 168(1):72-5. PubMed ID: 12050495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
    Mengs U; Witthohn K; Schwarz T; Lentzen H
    Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
    Galanina OE; Kaltner H; Khraltsova LS; Bovin NV; Gabius HJ
    J Mol Recognit; 1997; 10(3):139-47. PubMed ID: 9408830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary structure and molecular modeling of mistletoe lectin I from Viscum album.
    Eschenburg S; Krauspenhaar R; Mikhailov A; Stoeva S; Betzel C; Voelter W
    Biochem Biophys Res Commun; 1998 Jun; 247(2):367-72. PubMed ID: 9642133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.